Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ChemoMetec ASOCSE:CHEMM +0.52%98 Earnings Yield (Joel Greenblatt) % is 0.00% as of Dec. 2025. GuruFocus rates OCSE:CHEMM with a GF Score™ of 98/100 and a GF Value™ of kr531.16 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 850 Medical Devices & Instruments companies, ChemoMetec AS ranks better than 59.76% on this metric.
ChemoMetec AS's Enterprise Value for the quarter that ended in Dec. 2025 was kr11,694.4 Mil.
ChemoMetec AS's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was kr229.9 Mil. ChemoMetec AS's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2025 was 0.00%.
The historical rank and industry rank for ChemoMetec AS's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
OCSE:CHEMM'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 0.56 Med: 1.96 Max: 5.44
Current: 2.93
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of ChemoMetec AS was 5.44%. The lowest was 0.56%. And the median was 1.96%.
OCSE:CHEMM's Earnings Yield (Joel Greenblatt) % is ranked better than 59.76% of 850
companies
in the Medical Devices & Instruments industry
Industry Median: 0.845
vs OCSE:CHEMM: 2.93
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. ChemoMetec AS's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
ChemoMetec AS (OCSE:CHEMM) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
ChemoMetec AS Earnings Yield (Joel Greenblatt) % Related Terms
ChemoMetec AS Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for ChemoMetec AS's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ChemoMetec AS Earnings Yield (Joel Greenblatt) % Chart
For the Medical Devices subindustry, ChemoMetec AS's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ChemoMetec AS Earnings Yield (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ChemoMetec AS's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where ChemoMetec AS's Earnings Yield (Joel Greenblatt) % falls into.
ChemoMetec AS Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
ChemoMetec ASs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Jun. 2025 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of 0.00% mean?
ChemoMetec AS (OCSE:CHEMM) has a Earnings Yield (Joel Greenblatt) % of 0.00% as of Dec. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on ChemoMetec AS and its competitors. Over the past decade, ChemoMetec AS's Earnings Yield (Joel Greenblatt) % has ranged from 0.56 to 5.44. According to the industry distribution chart, ChemoMetec AS ranks #342 out of 850 companies in the Medical Devices & Instruments industry, placing it in the top 40.2%.
Is ChemoMetec AS's Earnings Yield (Joel Greenblatt) % too high?
ChemoMetec AS's current Earnings Yield (Joel Greenblatt) % is 0.00%. Over the past 10 years, this metric has ranged from a low of 0.56 to a high of 5.44. Based on the distribution chart, ChemoMetec AS ranks #342 out of 850 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, ChemoMetec AS has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ChemoMetec AS's Earnings Yield (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ChemoMetec AS ranks #342 out of 850 companies for Earnings Yield (Joel Greenblatt) %. This puts ChemoMetec AS in the upper half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 0.85. Historically, ChemoMetec AS's own Earnings Yield (Joel Greenblatt) % has ranged from 0.56 to 5.44 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median Earnings Yield (Joel Greenblatt) % among Medical Devices & Instruments companies is 0.85, based on 850 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on ChemoMetec AS and its competitors. For the Medical Devices & Instruments industry, the median Earnings Yield (Joel Greenblatt) % is 0.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ChemoMetec AS's current Earnings Yield (Joel Greenblatt) % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ChemoMetec AS stock overvalued right now?
Based on GuruFocus' analysis, ChemoMetec AS (OCSE:CHEMM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr531.16, compared to a current price of kr465.60 — trading 12.3% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 0.00%. ChemoMetec AS's overall GF Score™ is 98/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For ChemoMetec AS (OCSE:CHEMM), the current Earnings Yield (Joel Greenblatt) % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ChemoMetec AS (OCSE:CHEMM) Overvalued in 2026?
Based on GuruFocus' analysis, ChemoMetec AS stock appears to be undervalued.
The current stock price of kr465.60 is trading 12.3% below its estimated GF Value™ of kr531.16.
GuruFocus considers ChemoMetec AS to be Modestly Undervalued.
Key valuation signals for OCSE:CHEMM:
Earnings Yield (Joel Greenblatt) %: 0.00%
GF Value™: kr531.16 vs. price of kr465.60 (12.3% below fair value)
No single metric tells the full story. See the OCSE:CHEMM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.
98GF Score
Get the complete analysis for OCSE:CHEMM
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:CHEMM has been successfully added to your 
